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Objective. As recommended for subscribers to the WHO Global Health Sector Strategy on viral 
hepatitis, and to inform the development of a national strategic plan for Malaysia, we estimated 
the long-term burden incurred by the care and management of patients with hepatitis C virus 
(HCV) infection. We compared cumulative healthcare costs and disease burden under different 
treatment cascade scenarios. 
 
Methods. We attached direct costs for management/care of chronically HCV-infected patients to 
a previously developed clinical disease progression model. Under assumptions regarding: 
disease stage-specific proportions of model-predicted HCV patients within care, annual 
numbers of patients initiated on antiviral treatment, and distribution of treatments over stage, 
we projected the healthcare costs and disease burden (in DALY) in 2018-2040 under four 
treatment scenarios: (a) no treatment/baseline; (b) pre-2018 standard of care (pegylated 
interferon/ribavirin); (c) gradual scale-up in direct-acting antiviral (DAA) treatment uptake that 
does not meet the WHO 2030 treatment uptake target; (d) scale-up in DAA treatment uptake 
that meets the WHO 2030 target. 
 
Results. Scenario (d), while achieving the WHO 2030 target and averting 253,500 DALYs 
compared with the pre-2018 standard of care (b), incurred the highest direct patient costs over 
the period 2018-2030, of US$890 million (95% uncertainty interval: 653–1,271 million). When 
including screening programme costs, the total cost was estimated at US$952 million, which 




Conclusions. The scale-up to meet the WHO 2030 target may be achievable with appropriately 
high governmental commitment for the expansion of HCV screening to bring sufficient 
undiagnosed chronically-infected persons into the treatment pathway. 
 
Key Points for Decision-makers 
 WHO initiatives to greatly reduce the burden of HCV by 2030 have led many – mostly well-
resourced – countries to update national treatment policies to include the new and highly 
effective DAA therapies. 
 For the first time, we make available projections of the direct healthcare costs of HCV 
management under different treatment scenarios for Malaysia. 
 An enormous scale-up in screening activity and treatment uptake is needed to meet the 
WHO 2030 targets; due to savings in care costs this scale-up is only moderately more 








The World Health Organisation (WHO) Global Health Sector Strategy (GHSS) for hepatitis has 
set ambitious goals for reduction of the forecasted disease burden associated with chronic 
hepatitis C virus (HCV) infection, and eventual elimination (by 2030) [1]. In the action plan for 
the WHO Western Pacific Region (WPR), of which Malaysia is a participating country, plans 
for phased implementation of testing, treatment, and patient management services have been 
formulated [2], and interim targets for diagnosis of 30% of chronically-infected persons and for 
treatment of 50% of eligible patients were set for 2020. The corresponding WHO GHSS viral 
hepatitis targets for 2030 are 90% of chronically-infected persons diagnosed and 80% of eligible 
patients initiated on antiviral therapy, with a cure rate of 90%. The latter target depends on 
availability and delivery of treatment using all-oral direct-acting antivirals (DAA). 
 
Challenges in the timely expansion of service and care provision notwithstanding, a major 
hurdle to meeting the WHO treatment uptake targets using highly effective DAA therapies is 
affordability [3,4]. In the Asian region, relatively few HCV patients have received DAA 
treatment to date due to barriers to accessibility (i.e., availability or cost), and to entering the 
care pathway [5]. In Malaysia, recent governmental developments, namely the offer of a 
voluntary licensing agreement and the issuing of a compulsory license for sofosbuvir, will 
allow acquisition of DAAs at affordable prices. 
 
Reducing the currently high disease burden for many Asian countries is subject to numerous 
obstacles. To assist in national strategic planning, model-based projections of both the HCV 
disease burden, and the healthcare costs incurred for the management, care, and treatment of 
chronic HCV patients are valuable [1]. In previous work, a Markov model of the disease 
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progression pathway of HCV-related liver disease was developed for the Malaysian setting, 
and the disease burden was forecasted to the year 2039 assuming the best available standard of 
treatment: pegylated interferon/ribavirin (PegIFN/RBV) [6]. In the current analysis, we extend 
this disease burden projection model, attaching disease stage-specific healthcare costs to each 
patient-year and adopting the much more effective and tolerable DAA treatment, to project 
national-level annual HCV patient management and treatment costs.  
 
The main objective of this paper is therefore to estimate the future (long-term, from 2018 to 
2040) economic implications for the Malaysian healthcare system attributable to management 
of HCV patients. We compare the healthcare costs and disease burden, in disability-adjusted 
life-years (DALYs), under four treatment cascade scenarios: (a) no treatment; (b) pre-2018 
standard of care (PegIFN/RBV antiviral treatment), (c) all oral DAA treatment, with a gradual 
scale-up in annual treatment uptake that would not meet the WHO 2030 target; (d) DAA 
treatment with a scale-up in annual uptake to meet the 2030 target. The latter two scenarios 
assumes that sufficient expansion of screening/diagnosis and treatment services could be 
achieved to meet these targets. We combined the estimated costs for the expansion of screening 
with direct healthcare costs to arrive at a total cost for achieving the scale-up scenarios. 
 
2. METHODS 
2.1 Model description 
We calculated and attached direct patient care costs to an HCV disease progression model 
developed for the Malaysian setting. As in previous modelling work, clinical progression from 
acute HCV infection through liver-related death was simulated using an age-structured multi-
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state Markov model [6]. We expanded our previous model with three additional compartments 
(Fig. 1). Ethical approval and informed consent were not required for this modelling study. 
 
The model disease states are acute infection (AI), recovered (R), chronic infection (CI), 
moderate chronic hepatitis (MCH), compensated cirrhosis (CC), decompensated cirrhosis (DC), 
hepatocellular carcinoma (HCC) concurrent with CC, HCC concurrent with DC, and death 
from DC/HCC. MCH corresponds to Metavir stage F2-F3 (i.e., moderate/advanced fibrosis), 
and CC to Metavir stage F4. Two further states denote viral clearance through antiviral 
treatment, but without recovery from liver disease: CC-RNA– and DC-RNA–. The model 
parameters that describe the flow between disease states (annual transition probabilities 
between compartments), and excess mortality rates due to non-liver related causes were 
obtained from the literature (Online Resource, Table S1). Liver transplantation was not 
included as an additional pathway, as very few transplants are performed on HCV patients in 
Malaysia. 
 
The model cycle length was set at one year, and the clinical progression of cohorts of acutely 
infected patients comprising 86 age-groups was modelled, from <1 year through 85 years of 
age. For simplicity, all simulated patients were assumed to die after age 85. The simulation start 
year was 1960 (i.e., HCV was assumed to circulate from 1960), and the model was run up to 
and including 2040. The annual number of new acute infections was simulated using separate 
age-distributions for people who inject drugs (PWID) and non-PWID risk groups (see Ref. 6). 
Assumptions regarding HCV incidence over time were also adopted from the previous study 




2.2 Treatment cascade scenarios  
Healthcare cost and disease burden projections will depend on the number of chronically-
infected patients that are initiated on treatment. We describe each of the four scenarios 
explored below. For all scenarios, the historical annual numbers of patients initiated on 
treatment nationally were estimated based on interferon sales (R. Mohamed, pers. comm.). 
From these figures, an estimated 400, 450, 470, 450, 480, 645, 536, 554, 547 and 402 patients were 
treated from 2006 through 2015. For 2003 through 2005, 200, 300, and 350 patients were 
assumed to have been treated, with zero patients assumed treated prior to 2003. The estimates 
for 2016 and 2017 are lower, at 300 patients, as some patients were delaying treatment until the 
availability of DAA, patients with mild disease have been advised to continue clinical 
monitoring, and others have been recruited into clinical trials. All scenarios are identical up to 
the simulation year 2017; from 2018 differing assumptions regarding levels of treatment uptake 
and distribution of total treatments over disease stage influence the projections of both disease 
burden and annual direct costs. 
 
Genotype distribution and SVR rates. From data on patients who received antiviral therapy at 
Selayang Hospital between 2000 and 2014, the assumed genotype distribution was 64% G3 and 
36% G1/other [7]. Sustained virologic response (SVR) rates for interferon-based treatment of 
62% for G3 and 43% for G1/Other from the Malaysian routine care setting were adopted [8]. For 
DAA treatment, we adopted intention-to-treat SVR rates for CI and MCH stage patients of 88% 
[9] and 94% [10] for G3 and G1/Other, respectively. For CC and DC stage patients, the SVR rate 




Scenario A. No treatment. We included this as a baseline scenario to gauge the costs of care and 
management of patients with HCV-related liver disease alone. 
 
Scenario B. Pre-2018 standard of care. We defined this scenario to quantify the difference in the 
total cost of care and treatment using DAAs and the previous standard of care using interferon 
therapy. Prior to 2018, care guidelines issued by the Malaysian Ministry of Health were for 
interferon-based treatment; we assumed annual numbers of patients initiated on therapy at 
2017 levels (i.e., 300 patients per year). In this scenario, treatment is only given to patients 
within the moderate chronic hepatitis and compensated cirrhosis stages. 
 
Scenario C. DAA treatment, with gradual scale-up in treatment uptake. Starting with 1500 
patients treated with DAA in 2018, this annual number was increased by 500 per year 
throughout the rest of the simulation period. This scenario was devised on the basis of informal 
estimation of the annual increase that would allow expansion of screening and treatment 
services. 
 
Scenario D. DAA treatment, with treatment scaled-up to meet WHO GHSS 2030 uptake target. 
This scale-up to meet the WHO 2030 uptake target required a steep rise in the numbers of 
patients treated annually, from 5000 in 2018 climbing to 30,000 in 2025-2028, with the number 
decreasing to 5,000 patients per year initiated on treatment thereafter (Online Resource, Fig. 
S3).  
  
For scenarios C and D only, the estimated cost of a screening programme to deliver the 
required annual numbers of treated chronically-infected patients [12] was incorporated to 
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estimate the total economic burden. This stepwise strategy uses existing screening/diagnosis 
efforts as a starting point, followed by prioritised targetting of active and former PWID, with 
intensive general population screening as a final phase.  
 
For the scenarios involving DAA treatment (C and D), treatments were distributed over disease 
stage according to the distribution at initial presentation at Selayang Hospital (the national 
tertiary care referral centre for liver disease) [7]. Treatment was only considered viable for 
patients without HCC. For scenario C, treatments were distributed among untreated patients in 
the pre-HCC states throughout the entire simulation period as follows: CI=22%, MCH=48%, 
CC=26%, DC=4%. For scenario D, this distribution was used for 2018-2022; then, from 2023 
onwards the anticipated effect of scaled-up screening reaching more early-stage patients was 
simulated by increasing the percentages of CI and MCH patients receiving treatment and 
reducing the percentages of CC and DC, settling on the distribution CI=53.25%, MCH=45.25%, 
CC=1.0%, DC=0.5% in 2037-2040 (Online Resource, Fig. S1). With respect to interferon-based 
therapy (scenario B; all scenarios pre-2018), treatments were distributed among pre-cirrhotic 
(69%; all assumed in MCH stage) and cirrhotic (31%; all CC stage) patients only; this 
distribution was based on Selayang Hospital data [7]. 
 
2.3 DALY computation 
The composite DALY measure sums premature mortality (in years of life lost, or YLL), 
calculated as the number of deaths multiplied by the remaining life expectancy at age of death, 
and morbidity (in years lived with disability, or YLD), calculated as the number of prevalent 
cases multiplied by the disability weight [13]. The DALY for chronic HCV infection is therefore 
the sum of the YLL and YLD associated with all disease states following acute infection in the 
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progression model. We used the same disability weights as in the previous study [6, 14, 15], 
and adopted life expectancy values from the WHO Global Health Observatory [16]. 
 
2.4 Patients within care, and initiated on treatment 
As direct costs are attached only to patients in care, our projections require data on the annual 
numbers of patients in care within each disease stage (so costs associated with medical care and 
management can be estimated). We assumed that only symptomatic patients are in care, and 
estimated that 15% of CI and MCH patients, 60% of CC stage [17] and 100% of DC and HCC 
stage patients are symptomatic. Of the symptomatic patients only, 10% of CI and MCH stage, 
and 70%, 100%, and 100% of CC, DC, and HCC stage patients, respectively, were assumed to be 
in care and therefore incur costs (R. Mohamed, pers. comm.). 
 
For simplicity, we assumed that all referred patients incur antiviral treatment costs, including 
those that fail to start or complete treatment because of the following reasons: non-
compliance/refusal, deemed unsuitable by physician, death, or loss to follow up. As the SVR 
rates adopted were all from intention-to-treat study designs, we do not need to separately 
account for patients not completing therapy when calculating treatment costs. 
 
To achieve the high WHO treatment uptake target of 80% of all eligible chronically-infected 
persons in 2030 (scenario D), a corresponding steep scale-up in the annual numbers of patients 
entering the treatment pathway is also required. A comparable scale-up in screening/diagnosis 
would also be needed to ensure sufficient individuals for the next step of the cascade (referred 




2.5 Calculation of direct healthcare costs 
We used the public payer perspective, and calculated healthcare costs and resource use only. 
As our focus was on direct patient care/management costs, we excluded programme costs for 
screening and testing and the indirect costs of HCV disease; however, the estimated cost of an 
expanded screening programme was also taken into consideration (see 3.2 below). Future costs 
were inflation-adjusted according to a rate of 2.5% (estimated based on recent Consumer Price 
Indices (CPI)). All annualized costs are those within the public healthcare system as most of 
HCV treatment is performed within this system, although private healthcare options do exist in 
Malaysia. In view of highly subsidised public healthcare and the fact that the majority of HCV 
infections occurs within economically-disadvantaged populations such as PWID [18], most 
HCV care is performed at public healthcare facilities. DAA costs were calculated based on 
estimated prices through competitive market pricing by government negotiations with 
voluntary license manufacturers for sofosbuvir and velpatasvir at RM3000 per 12-week course. 
Ribavirin was estimated at RM360 per week. See Online Resource for further details on costing. 
Given recent announcements by the Malaysian Ministry of Health (MMH) of a RM1000 price 
tag for generic DAA under compulsory licensing to be provided to patients at 18 MMH 




Model outcomes, for each year of the period 2018-2040 were: (i) cumulative proportion of 
eligible patients who have been initiated on treatment (to evaluate WHO targets)(see Eq. 1 
below); (ii) cumulative proportion of eligible patients achieving SVR (see Eq. 2); (iii) total 
annualised costs per disease stage; (iv) cumulative DALYs due to chronic infection; and (v) 
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percent reduction in annual projected deaths from DC/HCC, compared with the annual 
modelled deaths in baseline year 2015. We define ‘eligible patients´ as those who are living 
with chronic HCV infection. Note that the percentage of eligible patients treated required to 
meet the WHO WPR 2020 target of 30% of chronically-infected patients diagnosed and 50% of 
diagnosed patients treated, is 15%. Similarly, for the WHO 2030 target year, the 90% diagnosed 
and 80% treated targets correspond to 72% (0.9 x 0.8) of eligible patients. 
 
We now describe how outcomes (i) and (ii) were calculated. The denominator of both Eq. 1 and 
Eq. 2, TotalEligible, is defined as the model-estimated number of living chronically-infected 
persons in the year 2015 (n=378,000; common to all four scenarios), and the numerator of each 
equation describes the cumulative number of treated patients (Eq. 1) or the cumulative number 












 (Eq. 2) 
 
Outcome (v) was included to evaluate the WHO target for a reduction in hepatitis C mortality. 
It is calculated simply as the projected number of deaths from DC/HCC in a given year of the 
simulation period, divided by the number for the year 2015 (n=1392). 
 
2.7 One-way sensitivity analysis 
For scenario D only, we investigated the impact on total cost (period 2018-2030) from 20% 
lower or higher values for parameters treated as constants: acute infection incidence from 2016, 
proportion of CI, MCH and CC stage patients who are symptomatic and in care. We also 
13 
 
calculated the total cost assuming universally lower DAA prices (i.e., available for all patients, 
not just for the 18 MMH hospitals), of RM1000 and a value in between, RM2000. 
 
2.8 Simulation procedure 
All model parameter values are summarised in Online Resource, Tables S1 and S2. The disease 
progression model was implemented and run using R version 3.2.0 [20]. Markov-chain Monte-
carlo (MCMC) sampling methods in a Bayesian framework were used to propagate uncertainty 
in model parameters to annual costs and DALY estimates. Sampling from the posterior 
distributions for each parameter was carried out via MCMC simulation using OpenBUGS 
version 2.2.2 [21] and the BRugs package for R [22]. Two thousand MCMC samples were 
discarded as burn-in, with the next 2,000 samples per chain forming the posterior distributions 
for all parameters. 
 
2.9 Model validation 
Validation of the model using recently proposed criteria [23] was carried out by the research 
team consisting of a modeller/epidemiologist, two hepatologists and two health economists. 
Consensus on input data (costs, disease progression and other model parameters) was achieved 
by considering the international literature and the Malaysian context. The costing 
methodology, including the perspective, time horizon, and calculation approach were 
considered appropriate and to adhere to standard recommendations for health economic 
research. All costs were collected through primary data collection and reflect the financial 
implications of treating and managing HCV disease within the standard clinical pathway in 
Malaysia and recent WHO treatment guidelines. Face validity of the conceptual model, input 
data, and outcomes were also verified. Model code was checked for logical correctness by 
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assuming a fixed size cohort of chronically infected HCV patients and then enumerating the 
number of persons progressing to each subsequent disease stage. Validation of model 
outcomes using alternative input data or against empirical data could not be conducted due to 
a lack of suitable data. 
 
3. RESULTS 
3.1 Direct cost estimates 
Table 1 shows annual direct healthcare costs per patient by disease stage, for all patients who 
have entered care. Costs were divided into the costs of patient management and care, and costs 
of treatment monitoring and drugs, with either interferon-based or DAA therapy. Values are in 
2018 currency (MYR) but were converted to US dollars (at the rate of one US$ = 4 Malaysian 
ringgit, the approximate exchange rate on 1 January 2018) for the projections. 
 
Annualised costs of management and care varied by disease stage due to differences in the 
healthcare resources used. For example, patients in the chronic infection and moderate chronic 
hepatitis (Metavir F0-F3) stages do not require day-care for oesophago-gastro-duodenoscopy 
procedures, in contrast to those patients in the CC and DC stages. Also, the type and frequency 
of investigations and non-HCV medication varied by disease stage.  
 
Compared with other disease stages, HCC concurrent with DC had the highest annual 
treatment cost due to complex and costly clinical management required from both hepatology 
and hepatobiliary departments. The cost of DC alone was 31 times higher than the cost of 




3.2 Cost forecasts 
The annual number of patients initiated on antiviral treatment over the period 2018–2040 
depends on the total number of treatments assumed, and the distribution over disease stage 
(Online Resource, Fig. S1). The number of patients eligible for treatment was set at the model-
projected number of chronically-infected patients in 2015: n=378,000. The cumulative 
proportion of patients initiating treatment reached the WHO 2030 target (72% of total eligible 
patients) in scenario D only (Online Resource, Fig. S3). The treatment scale-up in this scenario 
was inadequate, however, to meet the WHO WPR interim target for 2020 of 15% (7.6% of total 
eligible patients were initiated on treatment by 2020; Table S3). 
 
The estimated screening programme costs to deliver the needed annual numbers of chronically 
infected patients to be initiated on treatment for scenarios C and D are US$15 million and 
US$62 million [12], respectively. The higher cost for D is due to the extensive general 
population screening effort required. 
 
The annual projected patient care/management costs due to chronic HCV infection in Malaysia 
from 2018 until 2040 are compared across scenarios in Fig. 2. Scenario D shows a peaked 
pattern, with annual costs rising until 2025 and then dropping thereafter, mimicking the 
scaling-up assumed in the annual number of patients initiated on treatment. The remaining 
scenarios indicate rising burden, with the lowest burden for the ‘gradual DAA scale-up’ (C) 
and ‘no treatment’ (A) scenarios (Table 2). Although these two scenarios had the lowest 
projected cumulative direct costs for the period 2018-2030, this was offset by the 26% and 37% 





Combining direct patient costs with screening programme costs, scenario D was 12% more 
expensive (US$952 million vs. US$847 million) than scenario C (Table 2).  
 
For the gradual scale-up scenario (C), annual direct costs were projected to increase 1.4-fold by 
2040, from US$51 million (95% UI:34-77) in 2018 to US$70 million (95% UI:47-113) in 2040. For 
scenario (D), annual direct costs increased by approximately the same factor – 1.5-fold – 
between 2018 and the observed peak in 2025 (i.e., a consequence of the peak annual number of 
treated patients, n=30,000, being reached in 2025). The majority of the non-treatment costs (for 
the period 2018-2030) in scenarios B and C was for the management and care of patients in the 
CC, DC and HCC states: 95.5% and 91.2%, respectively; for scenario D this was much smaller, 
at 63.4%, due to advanced liver disease prevented. One-way sensitivity analyses conducted for 
scenario D indicated that the total cost for the period 2018-2030 was most sensitive to DAA 
pricing (Online Resource, Fig. S4). DAA prices of RM2000 and RM1000 reduced the median 
total cost by 9% and 18%, respectively. 
 
In scenarios C and D, a respective 9.5% and 38.7% of the cumulative direct healthcare costs to 
2030 were for treatment. The WHO target of a 65% reduction in mortality by 2030, compared 
with baseline year 2015, was not achieved in any scenario (Table S3), although for scenario D 
this target was achieved by 2036; the annual number of end-stage liver deaths were projected to 





In this study, we projected the economic implications for the Malaysian healthcare system for 
the care and management of patients with HCV infection, under various treatment cascade 
scenarios. The scenario that scaled up health service delivery to meet the WHO 2030 diagnosis 
and treatment uptake targets (scenario D) incurred the largest burden (in direct costs) over the 
period 2018-2030 – US$890 million (95% UI:653–1,270) – of which 39% was treatment-associated 
(including drugs) costs. This scenario also had the largest estimated impact on population 
health, by averting 253 thousand DALYs compared with baseline scenario (B) – the pre-2018 
standard of care (Table 2). The lower direct cost of the ‘gradual uptake' scenario (C) (US$832 
million over 2018-2030; 95% UI:556–1,259) was offset by a substantially smaller impact on the 
disease burden (72 thousand DALYs averted over 2018-2030 compared with baseline scenario 
B). Considering patient care/management costs only, scenario D was only modestly more 
expensive than C, as the increased treatment costs for scenario D are almost completely 
compensated by the saving in care costs. This was true even when screening programme costs 
are additionally included; the total economic burden for scenario D was only moderately 
higher (12%) than for C (Table 2). This difference will diminish in the event that DAA pricing is 
less expensive than assumed.  
 
Scenario D implements the projected enormous scale-up that would be required to meet the 
WHO 2030 treatment uptake target. We consider whether such a scale-up would be realistically 
achievable. Given that in many countries with high diagnosis/treatment rates, <5% of eligible 
patients have been initiated on treatment annually (estimates for the pre-DAA era [24]), it is 
unclear whether a scale-up in Malaysia from an estimated 1.1% of eligible persons in 2018 to 
72% in 2030 is within the realm of possibility. In terms of annual numbers initiated on DAA 
therapy, Egypt – with a population three times that of Malaysia and much higher HCV 
18 
 
prevalence – has made remarkable progress, treating 670,000 people between Oct 2014 and Sept 
2016 [25]. With the advent of DAA therapies in Australia, an estimated 30,400 to 33,400 persons 
were initiated on treatment between March and December 2016 [26], which suggests that the 
annual uptake in our scenario D could be achievable with sufficient governmental commitment 
and resources. Affordability of DAA would appear to no longer be a fundamental constraint, as 
the cumulative costs of care and treatment under DAA are highly similar to cost projections 
under the pre-2018 standard of care.  
 
For Malaysia – and other middle-income countries with endemic HCV – to meet the WHO 2030 
targets, or at least to reduce the disease burden to the levels projected within our ‘gradual scale-
up’ scenario C, many barriers must be overcome. Even if available at an affordable price, highly 
effective antiviral treatment is insufficient unless it can be delivered to those who need it (and 
are aware that a cure is possible). Expansion of HCV screening, disease assessment, and 
treatment services may pose a greater challenge than lowering drug prices. It is notable that the 
assumed number of patients within care for scenario D is far lower than the number of DAA-
treated patients required to meet the WHO 2030 target (Online Resource, Fig. S2). 
 
Diagnosis of 90% of all chronically-infected persons by 2030 requires an immense case-finding 
effort. Well-resourced countries that have intensively attempted this task, through 
improvement and scaling up of ancillary and other screening programmes, have not to date 
managed to diagnose more than about 80% of the chronically-infected population (e.g., 




In Malaysia, 28% (25,700/90,603) of HIV-infected individuals were estimated to be in treatment 
and care (i.e., receiving ART) in 2015 [28]. Given that HCV patients overlap substantially with 
HIV patients in terms of behavioural risk factors – a large proportion is PWID, who have poor 
access to healthcare – and may share rationale for the decision not to proceed along the 
healthcare pathway after receiving a positive diagnosis (e.g., not feeling unwell, difficulty in 
making appointments, anxiety about treatment side effects), the scaling-up of treatment uptake 
proposed in scenario C may be feasible. However, the estimated cumulative proportion of 
chronically-infected HCV patients initiated on treatment needed to meet the WHO 2030 target 
is 72% (achieved in scenario D only), much larger than the estimated proportion of HIV 
patients currently in contact with health services. This example from HIV suggests an 
important constraint on the expansion of HCV patient care within existing service providers: 
capacity needs to be greatly increased to accommodate increases in the size of the diagnosed 
population. The PWID population also pose challenges regarding linkage to care after 
diagnosis and especially with retention in care. In Australia, progression through the care 
cascade was historically subject to high attrition, as indicated by the small percentage (9%) of 
Australia's chronically-infected PWID treated by end of 2015 [29]. 
 
4.1 Limitations 
To estimate the main indicators for measuring the achievement of WHO 2030 targets – the 
cumulative percent of patients initiated on treatment and the reduction in annual number of 
end-stage liver disease (ESLD) deaths – we set the baseline year to 2015 (per Ref. 1). The 
prevalent number of living chronically-infected persons and number of ESLD deaths in 2015 
are model-based estimates, and so evaluation of target achievement depends on the validity of 
these figures. Finally, as there are no Malaysian incidence data, we needed to make modelling 
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assumptions regarding continuing transmission; thus, the expected annual growth of the HCV-
infected population means that evaluation with respect to 2015 may seem overly successful.  
 
4.2 Conclusions 
In Malaysia, the economic and disease burden attributable to HCV-related liver disease is 
projected to increase substantially over the coming two decades. This is due, in part, to ongoing 
viral transmission, but the majority of the direct costs will be incurred by persons infected in 
the 1990s or earlier who are now progressing to advanced disease stages. Although highly 
effective DAA are available at affordable prices, to significantly reduce the projected disease 
burden, treatment annual uptake needs to be scaled up massively. To meet the WHO GHSS 
targets of 90% diagnosed and 80% of diagnosed patients treated by 2030, treatment uptake 
scale-up would have to be steeper than currently considered viable, and depends on an 
enormous scale-up in screening/diagnosis and the provision of treatment and follow-up 
services. Both direct patient care/management costs and screening programme costs are 
essential for comparing the total economic burden across scenarios. These projections highlight 
the urgent need for better HCV control/preventive measures, and for supportive policies that 
lead to improved case-finding and consequent referral to care and initiation on effective 
antiviral therapy.  
 
Data Availability Statement. All parameter values/distributions for the natural history 
component, and all patient management/care and drug treatment costs for the economic 
component of the model are provided in the main paper and in the online resource. R/JAGS 
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Table 1. Direct costs for management and care (unit cost and frequencies) attached to patient-
years for each of the disease states: chronic infection(CI), moderate chronic hepatitis (MCH), 
compensated cirrhosis (CC) (untreated), CC (RNA-ve), decompensated cirrhosis (DC) 
(untreated), DC (RNA-ve), and hepatocellular carcinoma (HCC), and direct costs for patients 
entering the treatment pathway (ie. referred for treatment: CI, MCH, CC and DC states only). 
All values were computed in Malaysian ringgit. Bottom rows indicate costs for patients 
initiated on interferon-based (scenario B) or direct-acting antiviral (DAA) (scenarios C and D) 
treatment. 
Disease stage and cost category Unit cost Frequency 
Annualised cost  
(MYR in 2018) 
Chronic infection and moderate 
chronic hepatitis (Metavir F0-F3)   
   906.5 
   Outpatient visits 280.6 2 561.2 
   Investigation   345.3 
Compensated cirrhosis (CC)      1530.1 
  Outpatient visits 280.6 2 561.2 
  Investigation   479.7 
  OGDS at daycare   489.2 
Decompensated cirrhosis (DC)      27968.2 
   Outpatient visits 280.6 4 1122.2 
   Investigation (during admission and 
follow-up) 
  680.8 
   OGDS at day care 489.2 3 1467.8 
   Non-hepatitis C medication (during 
admission and follow-up) 
  13200.0 
   Admission  
6   
(ALOS: 5 days) 
11497.6 
HCC (concurrent CC)      15533.7 
   Management and care for CC   1530.0 
   Outpatient visits 392.4 2-5  803.1 
   Investigation (during admission and 
follow-up) 
  994.3 
   Admission  1-3  
(ALOS: 6-10 days) 
2842.5 
   Treatment (weightage) 
[TACE with DC beads (8%), TACE 
without DC beads (17%), RFA (23%), 
liver resection (7%)] 
  9363.8 
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HCC (concurrent DC)      41971.9 
   Management and care for DC   27968.2 
   Outpatient visits 392.4 2-5  803.1 
   Investigation (during admission and 
follow-up) 
  994.3 
   Admission  1-3  
(ALOS: 6-10 days) 
2842.5 
   Treatment (weightage) 
[TACE with DC beads (8%), TACE 
without DC beads (17%), RFA (23%), 
liver resection (7%)] 
  9363.8 
PegIFN/RBV course, 24 or 48 weeks*    
   Chronic infection and moderate 
chronic hepatitis (F0-F3) 
  19830.2 or 
35382.2 
   Compensated cirrhosis (CC)   20009.1 or 
35561.1 
DAA course      
   Chronic infection and moderate 
chronic hepatitis  
  4189.3 
   Compensated cirrhosis (CC)   4461.0 
   Decompensated cirrhosis (DC)   9184.6 
  
Note. ALOS=average length of stay; TACE= Transarterial chemoembolization; DC beads=drugs that are 
used in chemoembolization procedure together with cytotoxic drugs that help to gradually release the 
cytotoxic drug to targeted cancer cells therefore preventing systemic exposure of the cytotoxic drug3; 
RFA=radiofrequency ablation. *48 weeks indicated for HCV genotype 1 patients; 24 weeks for all other 
genotypes. Costs were assumed identical for CC (untreated) and CC (RNA-ve) stages, and for DC 
(untreated) and DC (RNA-ve) stages. 
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Table 2. Model-projected cumulative direct costs of management and care of chronic hepatitis 
C virus (HCV) infected patients in Malaysia, stratified by disease state, including costs incurred 
by patients initiated on antiviral treatment, estimated total costs including screening 
programme costs, and cumulative disability-adjusted life-years (DALYs) 2018–2030, under four 
different treatment cascade scenarios. Cumulative direct costs are calculated for the period 
2018–2030 (corresponding to the WHO Global Health Sector Strategy elimination target year). 
All costs are inflation-adjusted and are presented in US dollars. One US$ = 4.00 Malaysian 
ringgit. Cumulative costs are in millions and cumulative DALYs are in thousands. 95% 
uncertainty intervals are provided in parentheses. 
 
Disease state Scenario A Scenario B Scenario C Scenario D 
CI 14.5 14.5 30.6 151.1 
 (12.8-16.4) (12.7-16.4) (28.8-32.4) (149.3-152.8)  
MCH 4.9 24.9 39.9 155.5 
 (3.6-6.2) (23.7-26.2) (38.8-41.2) (153.2-155.5)  
CC 66.7 66.6 86.5 103.7 
 (44.9-94.6) (44.6-95.6) (65.4-114.9) (87.0-129.1)  
DC 712.7 704.9 621.6 430.4 
 (427.1-1121) (429.4-1111) (367.0-1015) (218.3-788.9)  
HCC 55.0 55.4 52.6 48.3 
 (27.5-99.7) (27.7-98.9) (25.4-94.6) (23.3-87.2)  
All states: direct 853.5 870.4 832.3 890.4  
 costs only (552.8-1297) (567.9-1294) (556.1-1259) (652.7-1271)  
Total cost incl.  –  – 847.4 952.4  
 screening – – (571.2-1274) (714.7-1333)  
All disease 946.3 944.6 872.7 691.1  
 states: DALYs (735.5-1212) (734.3-1204) (669.7-1130) (511.2-927.7) 
Note. CI = chronic infection; MCH = moderate chronic hepatitis; DC = decompensated cirrhosis; CC = 
compensated cirrhosis; HCC = hepatocellular carcinoma; DALY = disability-adjusted life-year. 
Scenario A: baseline, no treatment from 2018; B: pre-2018 standard of care, uptake PegIFN/RBV from 
2018 onwards set at estimated 2017 uptake level; C: DAA treatment; gradual scale-up in treatment 
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uptake; D: DAA treatment; scale-up in annual numbers initiated on treatment required to meet WHO 





Fig. 1 Multi-state hepatitis C virus clinical pathway model. Following successful direct-acting 
antiviral treatment, patients in the chronic infection (CI) and moderate chronic hepatitis (MCH) 
states move to the Recovered compartment; patients who achieve sustained virologic response 
in either the compensated cirrhosis (CC)-untreated or decompensated cirrhosis (DC)-untreated 
state move to the CC-RNA– or DC-RNA– state, respectively, but can still progress to 
hepatocellular carcinoma (HCC) or, for patients in the DC stage only, to end-stage liver-related 
death.  
Fig. 2 Annual direct cost projections for the management and clinical care (excluding 
screening) of patients with chronic hepatitis C virus infection in Malaysia, for the period 
2018–2040. Values are in US dollars (one US$ = 4.00 Malaysian ringgit) and adjusted for 
inflation. Four scenarios are compared: A. ‘no treatment’; B. ‘pre-2018 standard of care’; C. 
‘gradual scale-up of direct-acting antiviral (DAA) treatment uptake’; D. ‘scale-up of DAA 
treatment uptake adequate to meet WHO 2030 uptake target’. Shaded areas indicate 95% 
uncertainty intervals (point estimates only shown for scenario A, which almost completely 
overlaps with estimates for scenario B). 
 
